Search

Displaying results 7621 - 7630 of 9709 in total
  1. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    in a lower risk of off-target effects, including hepatotoxicity. … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results

  2. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune thrombocytopenia (ITP). ITP is an autoimmune disorde...

  3. Drug

    Sebetralstat

    go.drugbank.com/drugs/DB18305
    ApprovedInvestigational

    Hereditary angioedema (HAE) is a rare genetic disease that causes sudden, painful swelling episodes in various body locations that can be life-threatening, particularly when affecting the throat [L53533 … Sebetralstat is the first and only oral on-demand treatment for HAE, providing a convenient alternative to injectable therapies that have been challenging for patients to use [L53538, A274293].

  4. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    Aficamten is a cardiac myosin inhibitor.

  5. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    Zongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2).

  6. Drug

    Flurpiridaz F-18

    go.drugbank.com/drugs/DB18773
    Approved

    [A264519] Flurpiridaz F-18 is an analog of pyridaben, a mitochondrial complex 1 (MC-1) inhibitor.[L51659] … Flurpiridaz F-18 is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI), which is an imaging process used in patients with known or suspected

  7. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    Deuruxolitinib is a deuterated form of [ruxolitinib] that selectively inhibits Janus kinases (JAK) JAK1 and JAK2.

  8. Drug

    Dazostinag

    go.drugbank.com/drugs/DB18889
    Investigational

    Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

  9. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    [L53488] EGFR is a transmembrane protein with cytoplasmic kinase activity commonly expressed by non-small cell lung carcinomas (NSCLCs).

  10. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56122,L56123] It was the first new molecular entity approved under the Commissioner’s National Priority Voucher (CNPV) pilot program, achieving a regulatory decision just 50 days after filing.